McAdam LLC Sells 19 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

McAdam LLC lessened its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 0.7% during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 2,644 shares of the biopharmaceutical company’s stock after selling 19 shares during the period. McAdam LLC’s holdings in Regeneron Pharmaceuticals were worth $2,779,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of REGN. Gateway Investment Advisers LLC boosted its position in shares of Regeneron Pharmaceuticals by 13.7% during the first quarter. Gateway Investment Advisers LLC now owns 1,337 shares of the biopharmaceutical company’s stock valued at $1,287,000 after buying an additional 161 shares during the period. Wealthcare Advisory Partners LLC grew its position in Regeneron Pharmaceuticals by 14.4% in the 1st quarter. Wealthcare Advisory Partners LLC now owns 294 shares of the biopharmaceutical company’s stock valued at $283,000 after acquiring an additional 37 shares during the last quarter. Janiczek Wealth Management LLC increased its stake in Regeneron Pharmaceuticals by 20.1% in the first quarter. Janiczek Wealth Management LLC now owns 221 shares of the biopharmaceutical company’s stock worth $213,000 after purchasing an additional 37 shares during the period. Wealth Enhancement Advisory Services LLC lifted its position in shares of Regeneron Pharmaceuticals by 11.6% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 23,151 shares of the biopharmaceutical company’s stock worth $22,283,000 after purchasing an additional 2,412 shares during the last quarter. Finally, 180 Wealth Advisors LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the first quarter valued at $218,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Wall Street Analyst Weigh In

REGN has been the topic of a number of research reports. StockNews.com raised shares of Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Tuesday. JPMorgan Chase & Co. raised their price objective on Regeneron Pharmaceuticals from $1,150.00 to $1,200.00 and gave the stock an “overweight” rating in a report on Friday, August 2nd. Leerink Partnrs lowered Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 24th. Truist Financial cut their price target on Regeneron Pharmaceuticals from $1,200.00 to $1,137.00 and set a “buy” rating on the stock in a research note on Wednesday, October 16th. Finally, Barclays lowered their price objective on shares of Regeneron Pharmaceuticals from $1,220.00 to $1,080.00 and set an “overweight” rating for the company in a research note on Wednesday. One research analyst has rated the stock with a sell rating, four have issued a hold rating, sixteen have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $1,102.19.

Regeneron Pharmaceuticals Stock Performance

REGN opened at $941.39 on Thursday. The company has a market cap of $103.73 billion, a P/E ratio of 27.81, a price-to-earnings-growth ratio of 3.40 and a beta of 0.12. The company has a quick ratio of 4.62, a current ratio of 5.44 and a debt-to-equity ratio of 0.10. The firm’s 50-day moving average price is $1,098.29 and its 200-day moving average price is $1,040.67. Regeneron Pharmaceuticals, Inc. has a 52-week low of $769.19 and a 52-week high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $8.93 by $2.63. Regeneron Pharmaceuticals had a net margin of 32.04% and a return on equity of 16.80%. The business had revenue of $3.55 billion for the quarter, compared to analyst estimates of $3.38 billion. During the same quarter in the prior year, the business posted $8.79 EPS. Regeneron Pharmaceuticals’s revenue for the quarter was up 12.3% compared to the same quarter last year. As a group, equities analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 37.6 EPS for the current fiscal year.

Insider Activity at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of Regeneron Pharmaceuticals stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the completion of the sale, the chief financial officer now owns 15,305 shares of the company’s stock, valued at approximately $18,447,575.65. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In related news, VP Jason Pitofsky sold 487 shares of the firm’s stock in a transaction on Wednesday, August 7th. The shares were sold at an average price of $1,070.00, for a total transaction of $521,090.00. Following the completion of the transaction, the vice president now owns 4,204 shares of the company’s stock, valued at $4,498,280. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Christopher R. Fenimore sold 5,680 shares of the company’s stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the completion of the sale, the chief financial officer now directly owns 15,305 shares in the company, valued at approximately $18,447,575.65. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.48% of the stock is owned by insiders.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.